Ratings Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Real-time Estimate Cboe BZX Other stock markets 02:38:09 2024-06-10 pm EDT			5-day change	1st Jan Change
46.62 ^USD	-2.07%		+5.52%	+107.68%

Jun. 04	Goldman Sachs Adjusts Price Target on Agios Pharmaceuticals to $53 From $33, Maintains Neutral Rating	MT
Jun. 04	RBC Raises Price Target on Agios Pharmaceuticals to $53 From $44, Maintains Outperform Rating	MT

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
AGIOS PHARMACEUTICALS, INC.	+107.68%	2.7B	B-
VERTEX PHARMACEUTICALS INCORPORATED	+18.78%	125B	B+
REGENERON PHARMACEUTICALS, INC.	+13.77%	108B	B+
BIONTECH SE	-7.46%	24.21B	B+
ARGENX SE	+2.07%	22.78B	B
GENMAB A/S	-10.79%	17.96B	A-
WUXI APPTEC CO., LTD.	-41.74%	16.43B	A-
BEIGENE, LTD.	-14.09%	16.37B	B
NEUROCRINE BIOSCIENCES, INC.	+1.79%	13.58B	C+
SAREPTA THERAPEUTICS, INC.	+27.86%	11.66B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes